[Correction of endothelial dysfunction by L-arginine under experimental pre-eclampsia conditions]

M V Pokrovskiĭ; T G Pokrovskaia; V V Gureev; A A Barsuk; E V Proskuriakova; M V Korokin; O S Gudyrev; A S Belous; V I Kochkarov; L M Danilenko; O V Levashova; N V Mal'tseva; O S Polianskaia

[Correction of endothelial dysfunction by L-arginine under experimental pre-eclampsia conditions]

Eksp Klin Farmakol. 2012;75(2):14-6.

[Article in Russian]

Authors

M V Pokrovskiĭ, T G Pokrovskaia, V V Gureev, A A Barsuk, E V Proskuriakova, M V Korokin, O S Gudyrev, A S Belous, V I Kochkarov, L M Danilenko, O V Levashova, N V Mal'tseva, O S Polianskaia

PMID: 22550853

Abstract

The ADMA-like pre-eclampsia in pregnant rats was modeled by daily introduction of L-NAME in a dose of 25 mg/kg for 7 days. L-arginine (200 mg/kg) prevented the development of arterial hypertension and a decrease in placentary microcirculation and microalbuminuria. The possibility of using L-arginine for the prevention of competitive eNOS inhibition by ADMA is discussed.

Publication types

English Abstract

MeSH terms

Albuminuria / prevention & control
Animals
Arginine / administration & dosage*
Arginine / therapeutic use
Blood Pressure / drug effects
Endothelium / drug effects*
Endothelium / physiology
Female
Humans
Hypertension / prevention & control*
Injections, Intraperitoneal
Microcirculation / drug effects
Microcirculation / physiology
NG-Nitroarginine Methyl Ester / administration & dosage
NG-Nitroarginine Methyl Ester / adverse effects
Nitric Oxide Synthase Type III / metabolism
Placenta / blood supply
Placenta / drug effects*
Pre-Eclampsia / chemically induced
Pre-Eclampsia / drug therapy*
Pre-Eclampsia / metabolism
Pregnancy
Rats

Substances

Arginine
Nitric Oxide Synthase Type III
Nos3 protein, rat
NG-Nitroarginine Methyl Ester